Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb (BMS) and Pfizer have started patient enrollment in a Phase IV clinical trial called EMANATE (Eliquis evaluated in acute cardioversion coMpared to usuAl treatmeNts for AnTicoagulation in subjEcts with NVAF) evaluating the effectiveness and safety of Eliquis in patients with nonvalvular atrial fibrillation (NVAF) undergoing cardioversion.
Subscribe to our email newsletter
Currently, Eliquis is approved to reduce the risk of stroke and systemic embolism in patients with NVAF.
Cardioversion is a commonly used, effective method of converting atrial fibrillation to a normal rhythm, allowing the heart to pump more effectively.
Usually, anticoagulation is administered for a minimum of three weeks prior to cardioversion and for four weeks afterward.
In some patients, early cardioversion can be carried out on the same day or within days of new-onset NVAF, usually after imaging, to confirm the absence of a pre-existing thrombus in the heart, which could be dislodged during the cardioversion procedure and cause a stroke.
The trial is expected to enroll about 1,500 eligible patients from the US, Canada, Europe and Asia.
Bristol-Myers Squibb Cardiovascular Global Clinical Research vice president Jack Lawrence said, "This Phase IV trial will provide important data that will inform the use of Eliquis in patients with NVAF undergoing cardioversion."
Image: About 1,500 eligible patients from the US, Canada, Europe and Asia will be enrolled in the Phase IV EMANATE trial of Eliquis. Photo: courtesy of Michelle Meiklejohn/ freedigitalphotos.net